About Shinobi Therapeutics
Shinobi Therapeutics is a company based in San Francisco (United States) founded in 2023 by Shin Kaneko and Tobias Deuse.. Shinobi Therapeutics has raised $60 million across 2 funding rounds from investors including EQT, Life Sciences Partners and Eight Roads Ventures. Shinobi Therapeutics offers products and services including NJA-001, NJA-201, and NJA-301. Shinobi Therapeutics operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter San Francisco, United States
- Founders Shin Kaneko, Tobias Deuse
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Shinobi Therapeutics Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$60 M (USD)
in 2 rounds
-
Latest Funding Round
$59 M (USD), Grant
Aug 07, 2024
-
Investors
EQT
& 9 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Shinobi Therapeutics
Shinobi Therapeutics offers a comprehensive portfolio of products and services, including NJA-001, NJA-201, and NJA-301. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
iPS-based T cell therapy for solid tumors like HCC and CRC.
iPS-NK cell therapy targeting autoimmune diseases.
iPS-based T cell therapy for glioblastoma treatment.
Unlock access to complete
Leadership Team
2 people
Human Resources and Administration
1 people
Head Team
1 people
Sales and Marketing
1 people
Unlock access to complete
Funding Insights of Shinobi Therapeutics
Shinobi Therapeutics has successfully raised a total of $60M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $59 million completed in August 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Grant — $59.0M
-
First Round
First Round
(12 Dec 2023)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2024 | Amount | Grant - Shinobi Therapeutics | Valuation |
investors |
|
| Dec, 2023 | Amount | Series A - Shinobi Therapeutics | Valuation | Eight Roads Ventures , F-Prime Capital |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Shinobi Therapeutics
Shinobi Therapeutics has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include EQT, Life Sciences Partners and Eight Roads Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity investments in life sciences businesses are managed.
|
Founded Year | Domain | Location | |
|
Venture capital investment and global platform support for startups.
|
Founded Year | Domain | Location | |
|
Investments in life sciences, technology, healthtech, and crypto sectors from global locations.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Shinobi Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Shinobi Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Shinobi Therapeutics Comparisons
Competitors of Shinobi Therapeutics
Shinobi Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Shinobi Therapeutics
Frequently Asked Questions about Shinobi Therapeutics
When was Shinobi Therapeutics founded?
Shinobi Therapeutics was founded in 2023.
Where is Shinobi Therapeutics located?
Shinobi Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Who is the current CEO of Shinobi Therapeutics?
Dan Kemp is the current CEO of Shinobi Therapeutics.
Is Shinobi Therapeutics a funded company?
Shinobi Therapeutics is a funded company, having raised a total of $60M across 2 funding rounds to date. The company's 1st funding round was a Series A of $60M, raised on Dec 12, 2023.
What does Shinobi Therapeutics do?
Shinobi Therapeutics was founded in 2023 in San Francisco, United States, within the biotechnology sector. Allogeneic iPS cells with immune evasion properties, such as CD8ab iPS-T cells, are utilized by the company to create treatments for cancer and other conditions. Operations center on advancing cell-based therapies that address immune rejection challenges in allogeneic applications.
Who are the top competitors of Shinobi Therapeutics?
Shinobi Therapeutics's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does Shinobi Therapeutics offer?
Shinobi Therapeutics offers NJA-001, NJA-201, and NJA-301.
Who are Shinobi Therapeutics's investors?
Shinobi Therapeutics has 10 investors. Key investors include EQT, Life Sciences Partners, Eight Roads Ventures, Amed, and F-Prime Capital.